Form 4 CareDx, Inc. For: Oct 01 Filed by: Novack Jeffrey Adam
Jeffrey Adam Novack, Secretary and General Counsel of CareDx, Inc. (CDNA), filed a Form 4 indicating a transaction on October 1, 2026. The filing reports the disposition of 997 shares of common stock at a price of $66.23 per share to satisfy tax withholding obligations related to the vesting of restricted stock units. Following this transaction, Novack beneficially owns 105,078 shares of common stock.
Form 4 CareDx, Inc. For: Oct 01 Filed by: Meng Jessica
This Form 4 filing for CareDx, Inc. (CDNA) details a transaction by Jessica Meng, Chief Commercial Officer, on October 1, 2026. The filing indicates the withholding of 2,619 shares of common stock at a price of $66.23 to satisfy tax obligations related to the vesting of restricted stock units. Following this transaction, Meng beneficially owns 158,980 shares of common stock.
Caredx Inc stock hits 52-week high at 65.53 USD By Investing.com
CareDx Inc (CDNA) stock recently hit a 52-week high of $65.53, representing a 340% 1-year return and a market capitalization of $3.38 billion. Despite appearing overvalued by InvestingPro analysis, the company boasts a strong Piotroski Score of 9 and analysts predict profitability for the year. This follows strong Q2 2026 earnings, exceeding expectations, and positive analyst price target adjustments, highlighting robust financial performance and optimistic outlooks.
Caredx Inc stock hits 52-week high at 65.53 USD
CareDx Inc (CDNA) reached a 52-week high of $65.53, representing a 340% one-year return and a market capitalization of $3.38 billion. Despite being deemed overvalued by InvestingPro analysis, the company boasts a Piotroski Score of 9 and is expected to be profitable this year. This surge follows strong Q2 2026 earnings, where CareDx surpassed Wall Street expectations with an adjusted EPS of $0.37 and revenue of $132 million, leading to an increased full-year outlook and positive analyst ratings.
CareDx, Inc (CDNA) stock price, news, quote and history
This article provides a comprehensive overview of CareDx, Inc. (CDNA), including its current stock price, historical data, and key financial metrics. It highlights the company's focus on solutions for transplant patients and organ health, detailing various diagnostic and monitoring products. The report also includes performance benchmarks against the S&P 500, earnings trends, analyst insights, and valuation measures.
Caredx Inc stock hits 52-week high at 65.53 USD By Investing.com
CareDx Inc (CDNA) stock reached a new 52-week high of $65.53, marking a significant 340% return over the past year and a market capitalization of $3.38 billion. Despite appearing overvalued by InvestingPro analysis, the company boasts a perfect Piotroski Score of 9, strong Q2 2026 earnings exceeding expectations, and positive analyst outlooks with raised price targets. These factors highlight CareDx's robust financial health and market confidence in its leadership in transplant diagnostics.
CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?
CareDx (CDNA) shares surged 13% after BTIG raised its price target to $74 from $60, maintaining a Buy rating. The company reported a 52% year-over-year revenue increase in Q2 2026, driven by a 61% growth in Testing services. While earnings and revenue growth are positive, investors should monitor trends in earnings estimate revisions as the stock currently holds a Zacks Rank #2 (Buy).
BTIG raises CareDx stock price target to $74 on transplant outlook
BTIG has increased its price target for CareDx (NASDAQ:CDNA) to $74 from $60, maintaining a Buy rating, due to confidence stemming from a positive resolution of a transplant LCD, strong core business growth, and an exciting pipeline including the Naveris acquisition and AlloHeme test. The company's stock has risen 188% year-to-date, with a market capitalization of $2.81 billion, and reported strong Q2 2026 financial results, surpassing analyst expectations. Despite appearing overvalued by some metrics, its move into oncology is expected to support higher valuation multiples.
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
The Centers for Medicare & Medicaid Services (CMS) plans to adjust its 2027 clinical laboratory fee schedule to align with private sector rates, aiming to save $1 billion annually. This change impacts diagnostics companies differently: BillionToOne sees favorable reimbursement updates for its oncology test and mixed results for its prenatal segment, while CareDx receives favorable updates for its core organ transplant portfolio, with key tests largely unaffected or seeing modest increases.
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
The Centers for Medicare & Medicaid Services (CMS) plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates to save $1 billion annually. This change will involve payment reductions capped at 15% annually through 2029, with specific impacts varying across diagnostics companies. While broad categories face cuts, proprietary tests like BillionToOne's Northstar Response see increased reimbursement, and CareDx's core organ transplant portfolio, including AlloMap and AlloSure, shows a favorable outlook.
CareDx, Inc. (CDNA) stock price, news, quote and history
CareDx, Inc. (CDNA) stock was trading at $54.23, down 4.01%, as of 3:45 pm GMT-4. The company, which specializes in solutions for transplant patients and organ health, has seen its stock gain 187.82% YTD and 248.27% over the last year. Analysts have an average price target of $54.14, with a recent "Buy" rating from Canaccord Genuity at a $65 target.
A Look at CareDx Inc (CDNA) After 4.0% Gain -- GF Value $25.41 vs Price $56.49
CareDx Inc (CDNA) shares recently rose 4.0%, bringing its current price to $56.49, significantly above its 52-week low. Despite this strong performance, GuruFocus assesses the stock as significantly overvalued with a GF Value™ of $25.41, a P/E ratio much higher than its historical median, and substantial insider selling. The company holds an above-average GF Score™ of 65/100, though its valuation and profitability scores are low.
Caredx Inc stock hits 52-week high at 55.21 USD
CareDx Inc. (CDNA) stock hit a new 52-week high of $55.21, reflecting a 262% increase over the past year. Despite a suggestion from InvestingPro that the stock is overvalued at $41.06, strong Q2 2026 results and a perfect Piotroski Score of 9 contribute to investor confidence. Analysts maintain mixed ratings, with Canaccord Genuity setting a $65 price target and H.C. Wainwright reiterating a Neutral rating with a $46 target.
CDNA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 22, 2022 in the Class Action Filed on Behalf of CareDx, Inc. Limited Shareholders
The Klein Law Firm has announced a class action lawsuit against CareDx, Inc. (NASDAQ: CDNA) on behalf of shareholders who purchased common stock between February 24, 2021, and May 5, 2022. The complaint alleges that CareDx made false and misleading statements regarding its testing services revenue and demand, including improper marketing and inducements, leading to artificially inflated revenues and undisclosed regulatory risks. Shareholders have until July 22, 2022, to petition for lead plaintiff status.
Naveris × CareDx — 2025 rev $34,337,000 (audited Ex. 99.1)
This Dealroom.co article reports on Naveris, Inc.'s 2025 revenue of $34,337,000 USD, which was audited and sourced from CareDx's 8-K/A filing. The report also mentions that CareDx acquired Naveris for approximately $160 million in cash, with potential additional milestones, closing on July 1, 2026.
CareDx (NASDAQ: CDNA) CCO has 6,688 shares withheld for taxes
CareDx's Chief Commercial Officer, Jessica Meng, had 6,688 common shares withheld on September 12, 2026, to cover tax obligations related to the vesting of restricted stock units. The shares were valued at $52.37 each, and this was a tax-withholding disposition by the issuer, not an open-market sale. After this transaction, Meng directly holds 161,599 CareDx common shares.
Caredx Inc stock hits 52-week high at 53.71 USD
CareDx Inc. stock reached a 52-week high of $53.71, currently trading at $53.54 with a $2.74 billion market cap, reflecting a 275.74% 1-year increase. The company boasts strong financials with a Piotroski Score of 9 and a PEG ratio of 0.22, despite an InvestingPro analysis suggesting it's overvalued. Recent positive Q2 2026 results and analyst upgrades further highlight its strong market position.
CareDx (CDNA) CFO uses 8,220 shares to cover RSU taxes
CareDx, Inc. (CDNA) reported that its CFO & COO, Keith Kennedy, had 8,220 shares of common stock withheld on September 12, 2026, to cover tax liabilities related to the vesting of restricted stock units (RSUs). These shares were withheld by the company and not sold in the open market. Following this transaction, Kennedy directly holds 211,704 shares of CareDx common stock, with the withheld shares valued at $52.37 each.
Caredx Inc stock hits 52-week high at 53.71 USD By Investing.com
CareDx Inc. (CDNA) stock has reached a new 52-week high of $53.71, currently trading at $53.54, reflecting a significant 275.74% increase over the past year. The company shows strong financial health with a Piotroski Score of 9 and an attractive PEG ratio of 0.22, despite InvestingPro indicating it may be overvalued relative to its Fair Value. Recent positive news includes exceeding Q2 2026 earnings and revenue expectations, raising its full-year outlook, and receiving positive analyst coverage, signaling robust demand for its transplant diagnostics.
Caredx Inc stock hits 52-week high at 53.71 USD By Investing.com
Caredx Inc (CDNA) has reached a new 52-week high of $53.71, driven by strong investor confidence and impressive Q2 2026 results which surpassed Wall Street expectations. The company's stock shows a remarkable 275.74% 1-year change, boasts a Piotroski Score of 9, and a PEG ratio of 0.22. Analysts like Canaccord Genuity initiated coverage with a "buy" rating and a $65 price target, while H.C. Wainwright maintained a "Neutral" rating with a $46 price target.
CDNA Initiates Coverage by Canaccord Genuity -- Price Target Set at $65
Canaccord Genuity has initiated coverage on CareDx (CDNA) with a "Buy" rating and a price target of $65.00, despite GuruFocus indicating the stock is significantly overvalued at its current price of $48.77. The company, focused on precision medicine for transplant patients, shows strengths in financial stability and growth but weaknesses in valuation and has seen considerable insider selling. Investors are advised to exercise caution due to the overvaluation and mixed insider sentiment.
Canaccord initiates CareDx stock coverage with buy rating on testing By Investing.com
Canaccord Genuity initiated coverage on CareDx, Inc. (NASDAQ:CDNA) with a buy rating and a price target of $65, citing the company's leadership in transplant diagnostics and expanding oncology portfolio. Despite the stock's 254% surge over the past year, Canaccord believes its long-term growth potential is not fully reflected in current prices. CareDx also reported strong Q2 2026 financial results, exceeding Wall Street expectations for both EPS and revenue.
Canaccord initiates CareDx stock coverage with buy rating on testing
Canaccord Genuity initiated coverage on CareDx, Inc (NASDAQ:CDNA) with a buy rating and a price target of $65.00, citing the company's leadership in transplant diagnostics and expanding oncology diagnostics portfolio. Despite the stock's significant surge, analysis suggests it might be overvalued relative to its Fair Value. CareDx recently reported strong Q2 2026 financial results, exceeding expectations and raising its full-year outlook.
Caredx Inc stock hits 52-week high at 49.77 USD By Investing.com
Caredx Inc stock has reached a new 52-week high of $49.77, reflecting a robust 283.22% increase over the past year. Despite its current trading price of $49.69 and a market capitalization of $2.57 billion, InvestingPro Fair Value analysis suggests the company appears overvalued. The company recently reported strong Q2 2026 results, surpassing analyst expectations for both earnings and revenue, with total revenue up 52% year-over-year.
Caredx Inc stock hits 52-week high at 49.77 USD By Investing.com
Caredx Inc (CDNA) stock has reached a new 52-week high of $49.77, reflecting a robust 283.22% increase over the past year. Despite its current trading price of $49.69, InvestingPro's Fair Value analysis suggests the company might be overvalued, although it boasts a perfect Piotroski Score of 9 and an attractive PEG ratio of 0.2. This surge follows strong Q2 2026 results, where CareDx surpassed analyst expectations for both earnings and revenue, with total revenue rising 52% year-over-year to $131.9 million.
Caredx Inc stock hits 52-week high at 49.77 USD
Caredx Inc (CDNA) stock has hit a 52-week high of $49.77, trading at $49.69 with a market capitalization of $2.57 billion. This surge reflects a 283.22% increase over the past year, supported by a perfect Piotroski Score of 9 and an attractive PEG ratio of 0.2. The company recently reported strong Q2 2026 results, exceeding analyst expectations for both earnings and revenue, and raised its full-year outlook.
CareDx (NASDAQ:CDNA) Combines Strong Growth With a Bullish Technical Setup
CareDx (NASDAQ:CDNA) demonstrates strong revenue and earnings growth, coupled with a healthy balance sheet, making it an attractive prospect for growth investors. The company's technical setup indicates an emerging uptrend, with positive short-term and long-term trends and significant outperformance in the market. While the stock's P/E ratio is high and it has a history of negative earnings, its robust fundamentals and technical breakout align with a strategy for sustained growth.
ETFs Investing in CareDx, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of CareDx, Inc. The ETFs are sorted by their market value of CareDx, Inc. stocks and include details such as weight, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return. The list provides potential investment opportunities in CareDx, Inc. through diversified funds.
CareDx Inc (1K9) Q1 2026 Earnings Report - Results, Call & Slides
CareDx Inc. (1K9) has released its Q1 2026 earnings report, showing a significant beat on both EPS and revenue expectations. The company reported actual EPS of €0.30 against a consensus of €0.12, and actual revenue of €102.13M compared to an expected €88.53M, marking a nearly 39% year-over-year revenue growth. The earnings call took place on April 28, 2026, and the next earnings date is estimated for November 10, 2026.
Price to sales forward of CareDx, Inc. – NASDAQ:CDNA
This page from TradingView provides financial information for CareDx, Inc. (NASDAQ: CDNA), specifically focusing on its price to sales forward metric. The content highlights the company's financial data within the health technology sector.
CareDx (CDNA) Rallies On Growth Optimism, Is It Still 10% Undervalued?
CareDx (CDNA) has seen significant share price appreciation recently, with strong short-term and long-term gains. Despite this rally, Simply Wall St's analysis suggests the stock could still be 10.2% undervalued, with a fair value of $52.33 compared to its current price of $46.99. However, the article also notes a high P/E ratio relative to the industry and fair value, raising questions about valuation risk.
Price to book forward of CareDx, Inc. – NASDAQ:CDNA
This article displays the "Price to book forward" financial metric for CareDx, Inc. (NASDAQ: CDNA) on the TradingView platform. It indicates that the market was closed at the time of viewing, with no trades. The content primarily shows the navigation and footer elements of the TradingView website, with the core financial data point presented as "Period Value Change Change %".
Zacks.com featured highlights include CareDx, Healthcare Services, Forum Energy Tech, Amneal Pharma and Caterpillar
Zacks.com has identified five top-ranked, high-efficiency stocks expected to deliver strong returns: CareDx, Healthcare Services Group, Forum Energy Technologies, Amneal Pharmaceuticals, and Caterpillar. These companies were selected based on key efficiency ratios such as Receivables Turnover, Asset Utilization, Inventory Turnover, and Operating Margin, which indicate strong resource management and profitability potential. Each company has also demonstrated significant average four-quarter earnings surprises.
Price to book forward of CareDx, Inc. – DUS:1K9
This page provides financial data for CareDx, Inc. (DUS:1K9) on the Dusseldorf Stock Exchange, specifically focusing on its price to book forward metric. The content indicates that the market is currently closed with no trades. It also details the various data providers and copyright information for the financial data presented.
CareDx (NASDAQ: CDNA) insider lines up $423K stock sale
CareDx (NASDAQ: CDNA) insider Peter Maag has filed a Form 144 notice to sell 9,122 shares of common stock, valued at approximately $423,091. This planned sale involves restricted stock grants from June 2023 to July 2024 and follows previous sales by Maag in August 2026, totaling over 149,000 shares. The filing indicates 51,734,223 shares of CareDx common stock are currently outstanding.
CareDx (CDNA) insider Peter Maag files to sell 7,000 shares after large prior sales
Peter Maag, an insider at CareDx (CDNA), has filed to sell 7,000 common shares valued at $317,112.60 through Morgan Stanley Smith Barney LLC. This proposed sale follows several other significant common stock sales by Maag over the past three months, including blocks of 75,653, 46,963, and 27,332 shares. The company has 51,734,223 shares outstanding, and the stock is traded on NASDAQ.
Baron group trims CareDx (CDNA) stake to 3.75% in latest 13G/A
Baron Capital Group, including its affiliates BAMCO, Inc. and Baron Capital Management, Inc., and Ronald Baron, have filed an amended Schedule 13G for CareDx, Inc. (CDNA), reporting a beneficial ownership of 1,937,326 shares, which represents 3.75% of the company's common stock. This filing indicates that their ownership is now 5% or less, with shared voting and dispositive power over these shares, and clarifies that advisory clients hold the economic rights to dividends and sale proceeds. The previous stake was not explicitly stated, but the current filing signifies a reduction below the 5% threshold.
Does CareDx’s Profit Jump And Higher 2026 Outlook Change The Bull Case For CDNA?
CareDx, Inc. reported strong Q2 2026 results with significant profit and raised its full-year 2026 revenue outlook to US$490–500 million, while also managing its balance sheet through a buyback and ESOP filing. The article examines how this updated guidance impacts the investment narrative, particularly concerning growth, margins, and the ongoing risks associated with Medicare reimbursement policies. It also highlights differing analyst perspectives and encourages investors to conduct their own research, offering a comprehensive report for CareDx.
Does CareDx’s Profit Jump And Higher 2026 Outlook Change The Bull Case For CDNA?
CareDx (CDNA) reported strong Q2 2026 results with significant profit and raised its full-year 2026 revenue guidance to US$490–500 million, while also completing a share buyback and filing for an ESOP-related share registration. Despite this positive financial performance and a Medicare LCD confirming coverage for key tests, the company's investment narrative remains heavily influenced by potential future changes in Medicare policies and competitive pressures. Analyst opinions on CareDx's future earnings and valuation vary, highlighting the complexity of its long-term outlook.
CareDx (CDNA) insider Peter Maag files to sell 7,000 NASDAQ-listed shares
CareDx, Inc. insider Peter Maag has filed a notice to sell 7,000 shares of common stock, valued at $328,237.70, through Morgan Stanley Smith Barney LLC. These shares originated from restricted stock awards in late 2023 and early 2024. The filing also disclosed recent sales by Maag between August 4 and August 11, 2026, totaling over 120,000 shares for approximately $5.7 million.
Baron Discovery Fund Gains from Strategic Accumulation of CareDx (CDNA)
The Baron Discovery Fund increased its position in CareDx (CDNA) after shares declined in Q3 2025 due to a draft local coverage decision by CMS that threatened reimbursement for its diagnostic tests. The fund believed the stock was undervalued at $11-12, representing a worst-case scenario. CareDx's shares have since rebounded, reflecting better understanding of the CMS process and strong Q1 2026 results, including revenue growth and strategic acquisitions.
CareDx (CDNA) insider Peter Maag files to sell 7,000 shares after large prior sales
CareDx, Inc. (CDNA) insider Peter Maag has filed a Form 144 notice to sell 7,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, valued at $333,851 as of August 11, 2026. This proposed sale follows several large prior sales by Maag in the past three months, including 75,653 shares on August 4, 2026, for $3,576,851.19, and additional sales on August 5, 7, and 10, 2026. The filing indicates a consistent pattern of insider share disposals.
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 7, 2026
CareDx, Inc. announced inducement grants of restricted stock units (RSUs) to 35 new employees as a material incentive for their employment. A total of 97,090 shares of common stock were awarded, with most RSUs vesting over four years and one employee's RSUs vesting 100% after one year, subject to continued service. These awards were made under the company's 2025 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
This Insider Has Just Sold Shares In CareDx
CareDx's Independent Chairman, Michael Goldberg, recently sold US$2.1m worth of stock, reducing his holding by 24%. While significant, the sale occurred at current prices, making it less concerning than a sale at a lower price. Despite the insider selling, CareDx maintains strong insider ownership at 4.6% and is a profitable, growing company, though some caution is advised due to past sales and identified warning signs.
Statutory Earnings May Not Be The Best Way To Understand CareDx's (NASDAQ:CDNA) True Position
CareDx, Inc. (NASDAQ:CDNA) recently reported strong earnings, leading to a share price increase. However, an analysis of the accrual ratio revealed that its free cash flow significantly lagged its statutory profit, partly due to unusual items boosting profit. The article suggests that while headline numbers look good, the underlying earnings power might not be as strong as a superficial glance at statutory profits would suggest.
This Insider Has Just Sold Shares In CareDx
CareDx's Independent Chairman, Michael Goldberg, recently sold US$2.1m worth of shares, reducing his total holding by 24%. While this is the largest insider sale in the past year, the shares were sold at a price close to the current market value. Despite no insider purchases in the last year, the company's profitability, growth, and high insider ownership (4.6%) temper concerns from the share sales.
State Street (CDNA holder) discloses 2.47M CareDx shares under shared control
State Street Corporation has reported a beneficial ownership of 2,468,858 shares of CareDx, Inc. common stock, which represents 4.8% of the class, according to a Schedule 13G SEC filing. All voting and dispositive authority for these shares is shared through affiliated investment adviser entities. The filing indicates that State Street holds less than 5% of CareDx's common stock, classifying it as a passive investment.
CareDx (CDNA): Neil Gagnon and Gagnon entities report 4.4% ownership stake
Neil Gagnon and his affiliated entities, Gagnon Securities LLC and Gagnon Advisors, LLC, have reported a collective ownership stake of 4.4% in CareDx, Inc. (CDNA) common stock through a SCHEDULE 13G/A SEC filing. Neil Gagnon individually beneficially owns 2,293,464 shares (4.4%), while Gagnon Securities LLC holds 1,629,867 shares (3.2%) and Gagnon Advisors, LLC holds 408,837 shares (0.8%). The filing details the sole and shared voting and dispositive powers over these shares, clarifying that beneficial ownership of client-held securities is disclaimed.
CareDx (NASDAQ: CDNA) insider Peter Maag plans 27,332-share stock sale after option exercise
CareDx, Inc. insider Peter Maag has filed to sell 27,332 shares of Common Stock, which are tied to a stock option exercise dated August 7, 2026. The sale will be executed on NASDAQ through Morgan Stanley Smith Barney LLC’s Executive Financial Services program. The filing also discloses prior sales by Maag of 46,963 shares on August 5, 2026, valued at $2,178,945.34, and 75,653 shares on August 4, 2026, valued at $3,576,851.19.
Statutory Earnings May Not Be The Best Way To Understand CareDx's (NASDAQ:CDNA) True Position
CareDx's recent strong earnings report was met with a positive market response, but an analysis of its financial ratios reveals underlying issues. The company's high accrual ratio of 0.28 suggests its free cash flow significantly lagged its statutory profit, indicating that non-recurring unusual items heavily boosted reported earnings. This analysis suggests that CareDx's statutory profits may not accurately reflect its true underlying financial health.
